Ava Manning, MD
Obstetrics & Gynecology · Houston, TXNPI 1710048970
Payments from drug & device makers
Across 155 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$671
- Pfizer$306
- AbbVie$266
- Astellas Pharma US Inc$245
- Daiichi Sankyo Inc.$179
- Exeltis, USA Inc.$136
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,820100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 31 | $671 |
| Pfizer | 25 | $306 |
| AbbVie(2 entities) | 15 | $266 |
| Astellas Pharma US Inc | 11 | $245 |
| Daiichi Sankyo Inc. | 8 | $179 |
| Exeltis, USA Inc. | 7 | $136 |
| Organon | 6 | $103 |
| Coopersurgical, Inc. | 6 | $98 |
| Myovant Sciences Inc. | 5 | $92 |
| Avion Pharmaceuticals | 5 | $92 |
| Hologic Sales And Service, LLC | 2 | $57 |
| Aspira Women's Health Inc | 2 | $53 |
| Merck | 3 | $51 |
| Mayne Pharma Commercial LLC | 2 | $45 |
| Medtronic | 2 | $33 |
| Sage Therapeutics, LLC | 2 | $32 |
| Evofem Biosciences, Inc. | 2 | $31 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Therapeuticsmd, Inc. | 2 | $30 |
| Convatec Inc. | 2 | $28 |
| Covidien LP | 2 | $27 |
| Mycovia Pharmaceuticals, Inc. | 1 | $26 |
| Meditrina | 2 | $25 |
| Pacira Pharmaceuticals Incorporated | 1 | $23 |
| AstraZeneca | 1 | $23 |
| Acessa Health Inc. | 2 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Heron Therapeutics, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Amgen | 1 | $15 |
| Lupin Inc. | 1 | $12 |
How this compares
$2,820 in reported general payments places this provider in the 70th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 113 | $47,936 |
| Estradiol | 516 | $43,977 |
| ImvexxyEstradiol | 15 | $10,190 |
| YuvafemEstradiol | 55 | $9,646 |
| EstringEstradiol | 17 | $8,256 |
| PremproEstrogen,con/M-Progest Acet | 11 | $7,749 |
| ValacyclovirValacyclovir Hcl | 79 | $4,030 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 33 | $3,464 |
| Estradiol (Once Weekly)Estradiol | 25 | $3,191 |
| Estradiol (Twice Weekly)Estradiol | 22 | $2,640 |
| Clobetasol Propionate | 19 | $474 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $286 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 18 | $260 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $223 |
| Triamcinolone Acetonide | 19 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Estring, Prempro | $306 | $63,940141 claims |
| Therapeuticsmd, Inc.Imvexxy | $30 | $10,19015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,099 obstetrics & gynecology providers in Texas.
Other obstetrics & gynecology in Houston
- Amir JazaeriHouston$19.5M
- Shannon WestinHouston$17.3M
- Mark JacobsHouston$2.8M
- Sandra HurtadoHouston$1.7M
- Dawn BlackHouston$1.2M
- George KuhnHouston$244K
- Luis Sandoval-MartinezHouston$234K
- Daisy AyimHouston$188K
- Asha BhalwalHouston$151K
- Monica LopezFort Worth$8.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.